Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Why is Moderna stock sliding today?

Moderna's stock is experiencing a 3.8% decline today, dipping to a low of $212.50. The company's recent Analyst Day in early November shed light on its projected annual cash costs of $4 billion through 2027, and even $4 billion to $4.5 billion per year through 2030, marking a significant increase from $2.1 billion in 2025. Additionally, management postponed any formal 2027 revenue guidance to the upcoming fourth-quarter earnings call, creating a noticeable visibility gap for investors.

Moreover, Moderna's Phase 3 interim results for its norovirus vaccine did not meet early success criteria, further complicating the stock's near-term outlook. The company's valuation stands high relative to its 52-week low of $22.28 and even relative to analyst price targets, leaving little room for disappointment. Insider trading activity, including President Stephen Hoge's sale of $11.7 million in common stock and collective insider disposals of $33.9 million in shares over the past 90 days, has also contributed to the stock's downward trajectory.

Despite the addition of Moderna to the MSCI World Index, slated for November 30, the broader market conditions, with the Nasdaq Composite down 1.8% and the S&P 500 off 1.2% in morning trading, add to the pressure. The AI and growth trade remains turbulent, and Moderna's high-beta profile amplifies these risks. The stock has retreated from its 52-week high of $280.80, despite the company's underlying mRNA platform's long-term potential through its cancer vaccine collaboration with Merck and newly approved influenza vaccines.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in Finance & Markets

More from Monday 16 November →